long-termextensionofmrz-9605reisbergetal-华译网翻译公司.pdf

long-termextensionofmrz-9605reisbergetal-华译网翻译公司.pdf

  1. 1、本文档共4页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
翻译样稿北京华译网翻译公司翻译样稿北京华译网翻译公司翻译样稿北京华译网翻译公司的长期扩展研究等为期周的双盲研究结束后名完成试验者美金刚组或者安慰剂组被再次滴定并继续周开放的美金刚研究每天患者在最初的周治疗期保持盲态在双盲期美金刚组患者的恶化速度明显慢于安慰剂组在长期有效性分析中有效性评价方法评价了患者周期间的恶化程度评价指标涉及整翻译样稿北京华译网翻译公司翻译样稿北京华译网翻译公司体状况功能及认知能力结果在扩展期前面服用安慰剂的患者改为服用美金刚后患者的恶化程度明显减慢在整体状况功能及认知能力三

翻译样稿(Translation Sample) 北京华译网翻译公司(Beijing HuayiNet Translation Company) Long-term extension of MRZ-9605 (Reisberg et al, 2006)58 Following on from the 28-week, double-blind phase of study MRZ-9605, 175 ‘completers’ (memantine or placebo) were re-titrated and continued on open-label memantine (20 mg/day) for a further 24 weeks. Patients remained blinded to their initial 28-week treatment. In the double-blind phase, patients who took memantine declined at a significantly slower rate than those who took placebo.10 In the long-term analysis, efficacy measures assessed the rate of decline in patients over the whole 52-week period, in the domains of global status, function and cognition. Results • The rate of decline in patients in the former placebo group slowed significantly upon their switch to memantine in the extension phase – the change in rate of decline was statistically significant in all three domains (Figure 6.18). • The rate of decline in patients who received memantine in both phases of the study varied across efficacy measures. Comparing outcome in the open-label phase with the double-blind phase, the rate of global decline decreased significantly (p0.001, OC analysis), the rate of cognitive decline remained unchanged, and the rate of functional decline increased (Figure 6.19). Long-term extension of Lu-99679 (Bakchine et al, 2007)59 The 148-week extension of study Lu-99679 assessed the decline/rate of disease progression of patients treated with memantine compared to untreated patients, and TEAEs between groups. Completers of the 24-week, randomised, double-blind, placebo-controlled, 6-month

文档评论(0)

wangsux + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档